Monographie - Amphotericin B lipid complex

Ostatnia aktualizacja :
19/11/2024

Amphotericin B lipid complex

Struktura chemiczna

Nazwa handlowa

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Abelcet

Argentyna, Australia, Austria, Belgia, Brazylia, Dania, Finlandia, Francja , Grecja, Hiszpania, Holandia, Irlandia, Kanada, Luksemburg, Malezja, Meksyk, Niemcy, Norwegia, Peru, Portugalia, Rumunia, Stany Zjednoczone Ameryki, Szwecja, Węgry, Wielka Brytania, Włochy

Bibliografia : Amphotericin B lipid complex

	typ	publikacja
1510	Książka	AHFS Formulary service 2000 Bethesda - 3546 p
2247	Czasopismo	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Czasopismo	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3254	Czasopismo	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratorium	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3644	Laboratorium	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3828	plakat	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	plakat	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	Czasopismo	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44

Mentions Légales